DMXAA

DRUG2 trials

Sponsors

Antisoma Research, Cancer Research UK

Conditions

Refractory TumorsSolid Tumors

Phase 1

Phase I Safety Study of DMXAA in Refractory Tumors

CompletedNCT00856336

Antisoma ResearchRefractory Tumors

Start: 2003-05-31End: 2004-01-31Updated: 2009-03-05

Study of DMXAA (Now Known as ASA404) in Solid Tumors

CompletedNCT00863733

Cancer Research UKSolid Tumors

Start: 1996-05-31End: 2000-03-31Updated: 2009-03-18

Related Papers

Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials.

2009-04-2212 citations